NYSE: OME Date: 2/26/15
Recommendation
BUY Key Statistics
Sector: Consumer Goods Industry: Processed & Packaged Goods Market Cap:
$238 M
Trailing P/E: 5 Yr Average: Industry Avg:
9.6 14.6 14.7
Forward P/E:
9.85
P/S: Industry Avg:
.87 2.71
P/B: Industry Avg:
.89 3.17
EV/EBITDA:
3.8
Beta:
1.6
ROA: ROE:
9.5% 10.0%
Fair Value: $13
Price: $11
Target Price: $18
Company Overview
Omega Protein Corporation manufactures Omega-3 fish oil, specialty fish products, and nutritional supplements for sale to various feed manufactures and wholesale organic distributors. The company operates in two segments: Animal Nutrition and Human Nutrition. The Animal Nutrition segment harvests fish (menhaden) to produce fish meal, crude fish oil, refined fish oil, and fish solubles. The Human Nutrition segment offers protein products, Omega-3 fish oil supplements and operates as an ingredient supplier for the nutraceutical industry.
1 - Year Price Performance OME
50%
S&P 500
25%
0%
Feb-‐14 Mar-‐14 Apr-‐14 May-‐14 Jun-‐14 Jul-‐14 Aug-‐14 Sep-‐14 Oct-‐14 Nov-‐14 Dec-‐14 Jan-‐15 Feb-‐15
Investment Thesis
• Growing demand from consumers becoming more conscious about their health • Increased product offerings in Human segment will drive revenue growth • Acquisitions of Cyvex (12/10) and InCon (9/11) enable vertical integration and differentiate its fish oil from substitutes • Acquisition of Bioriginal (9/14)creates steady revenue stream for Human segment to hedge against seasonality in the Animal segment • Fish oil from menhaden is the only oil approved by the FDA • Consistent catch of menhaden will provide Omega with consistent revenue as demand for fish meal and fish oil grow • Acquisition of Wisconsin Specialty Protein (2/13) expands presence into specialty protein market and brings added value to its product line
Catalysts • Increasing pork production • Growing aquaculture environment • Plant nutrition • Sales price of fish oil and fish meal to animal end markets • Human supplements
Risks • New entrants into menhaden fishing market • Government / FDA regulations adversely affect the firm’s ability to catch menhaden • Energy swap adjustments and seasonality Omega’s animal segment could dilute earnings more than anticipated • Reliance on menhaden fish
Muma College of Business | Analysts: Haomin Chen, Daniel Dorman, and Matt Errico
1